Clinical Trial Update: Effectiveness of CRD-740 in Heart Failure [Phase 2]

View source ↗

Summary

Cardurion Pharmaceuticals reports the Phase 2 trial of CRD-740 in heart failure has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Heart Disease
• Heart Failure
• Heart Failure with Preserved Ejection Fraction
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• CRD-740

Snippet

Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: TERMINATED | Results posted: 2024-12-19